The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.

Risa Liang Wong,Sarah K. Holt,Jing Zeng,Laura A. Graham,Rachel Kang,Nathan Conrad,Andrea Toulouse,Zoya Bauer,Michael Lai,Todd Yezefski,Jonathan L. Wright,Emily Steinberger Weg,Andrew C. Hsieh,Heather H. Cheng,Jean H. Lee,Delphine L. Chen,Daniel W. Lin,Evan Y. Yu

The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.

2021

Risa Liang Wong
Sarah K. Holt
Jing Zeng
Laura A. Graham
Rachel Kang
Nathan Conrad
Andrea Toulouse
Zoya Bauer
Michael Lai
Todd Yezefski
Jonathan L. Wright
Emily Steinberger Weg
Andrew C. Hsieh
Heather H. Cheng
Jean H. Lee
Delphine L. Chen
Daniel W. Lin
Evan Y. Yu

TPS5099Background: Patients with biochemical recurrence (BCR) after local definitive therapy for prostate cancer (PC) represent the largest group of patients alive with PC in the United States. For...

Keywords:

Internal medicine
Medicine
breakpoint cluster region
Oncology
Prostate cancer
PET-CT
Biochemical recurrence
Definitive Therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations